This site is intended for U.S. healthcare professionals only.

Contact Us

If you have any questions or inquiries about CLEVIPREX® (clevidipine) or our other products, please use the information below to contact us.

Contact Chiesi USA, Inc.

Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-466-6505

Medical Information

To request specific medical information about CLEVIPREX® or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.

Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-661-9260

Fax:
1-866-443-3092

Email:
US.Medical@chiesi.com

Important Safety Information

CLEVIPREX® (clevidipine) Injectable Emulsion is contraindicated in patients with:

  • Allergies to soybeans, soy products, eggs, or egg products;
  • Defective lipid metabolism seen in conditions such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and
  • Severe aortic stenosis.

CLEVIPREX® is intended for intravenous use. Use aseptic technique and discard any unused product within 12 hours of stopper puncture.

Hypotension and reflex tachycardia are potential consequences of rapid upward titration of CLEVIPREX®. If either occurs, decrease the dose of CLEVIPREX®. There is limited experience with short-duration therapy with beta-blockers as a treatment for CLEVIPREX®-induced tachycardia. Beta-blocker use for this purpose is not recommended.

CLEVIPREX® contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism.

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.

CLEVIPREX® is not a beta-blocker, does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.

Patients who receive prolonged CLEVIPREX® infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

There is no information to guide use of CLEVIPREX® in treating hypertension associated with pheochromocytoma.

Most common adverse reactions for CLEVIPREX® (>2%) are headache, nausea, and vomiting.

See Full Prescribing Information

www.cleviprex.com

This site is intended for U.S. healthcare professionals. If you are a U.S. healthcare professional, click OK to continue.

Cancel
Ok